FDA Slams Fresenius Over Leaking Dialysis Bags, Warns of Potentially Life-Threatening Risk
FDA warns Fresenius over Utah plant violations, citing leaking dialysis bags and visual inspection failures. Read the full compliance update.
Stocks · News reference
Fresenius Medical Care Publishes Global Study On Hemodiafiltration Associated With Lower Relative Risk Of Death From Conventional High-Flux Hemodialysis
Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with kidney diseases, today announced the publication of a large international study reporting that
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Can Fresenius Medical's 5008X Rollout Drive the Next Growth Phase?
Fresenius Medical Care is scaling up its 5008X CAREsystem rollout, converting 227 U.S. clinics to the new technology by July 2026, representing 10% of its machine base. The company has performed over 600,000 treatments including 100,000+ high-volume hemodiafiltration treatments, showing clinical promise with 40% fewer muscle cramps. However, near-term headwinds include weak U.S. treatment volume growth (-0.9%), TDAPA reimbursement pressure (€50 million drag expected), and significant rollout implementation costs.
Bernstein Maintains Market Perform on Fresenius Medical Care, Raises Price Target to $25.8
Bernstein analyst Lisa Clive maintains Fresenius Medical Care (NYSE:FMS) with a Market Perform and raises the price target from $25.5 to $25.8.